Janssen-Cilag International NV, of Beerse, Belgium, a unit of Johnson & Johnson, said the European Commission approved a variation to the marketing authorization for Velcade (bortezomib) in the additional indication of previously untreated mantle cell lymphoma in adults who are not suited for blood stem cell transplantation, in combination with Rituxan (rituximab, Biogen Idec Inc./Roche AG), cyclophosphamide, doxorubicin and prednisone.